Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4A | O75164 | 1/20 | 0.43 |
| ▸ | CTSS | P25774 | 10/20 | 0.40 |
| ▸ | CTSK | P43235 | 7/20 | 0.40 |
| ▸ | CA12 | O43570 | 3/20 | 0.39 |
| ▸ | CA1 | P00915 | 3/20 | 0.39 |
| ▸ | CA2 | P00918 | 3/20 | 0.39 |
| ▸ | CA9 | Q16790 | 3/20 | 0.39 |
| ▸ | CTSL | P07711 | 2/20 | 0.38 |
| ▸ | CTSB | P07858 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL589320 | 0.99 | KDM4A (0.42) | KDM4ACTSSCTSKCA12CA1 | |
| SCHEMBL31486392 | 0.80 | KDM4A (0.44) | KDM4ACTSKCA12CA1CA2 | |
| SCHEMBL130176 | 0.80 | PRMT6 (0.47) | KDM4ACA12CA1CA2CA9 | |
| SCHEMBL10266596 | 0.80 | KDM4A (0.44) | KDM4ACTSKCA12CA1CA2 | |
| SCHEMBL4951322 | 0.79 | GPR119 (0.33) | CTSSCTSKCTSLCTSB | |
| SCHEMBL11312324 | 0.79 | KDM4A (0.41) | KDM4ACTSSCTSKCA12CA1 | |
| SCHEMBL4068147 | 0.78 | KDM4A (0.43) | KDM4ACTSKCA12CA1CA2 | |
| SCHEMBL352926 | 0.78 | KDM4A (0.43) | KDM4ACTSKCA12CA1CA2 | |
| SCHEMBL13975464 | 0.78 | KDM4A (0.43) | KDM4ACTSKCA12CA1CA2 | |
| SCHEMBL15184496 | 0.78 | KDM4A (0.43) | KDM4ACTSKCA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8835441-B2 | Heterobicyclic metalloprotease inhibitors | AMGEN INC. (US) | 2014-09-16 | — | — | US | disclosed |
| US-8822474-B2 | 6,7-dihydrothieno[3,2-d]pyrimidine for the treatment of inflammatory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-09-02 | — | — | US | disclosed |
| US-8822474-B2 | 6,7-dihydrothieno[3,2-d]pyrimidine for the treatment of inflammatory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-09-02 | — | — | US | disclosed |
| US-20140005154-A1 | 6,7-Dihydrothieno[3,2-d]pyrimidine for the Treatment of Inflammatory Diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-02 | — | — | US | disclosed |
| US-8604039-B2 | Dihydrothienopyrimidines for the treatment of inflammatory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-12-10 | — | — | US | disclosed |
| US-20120108534-A1 | Dihydrothienopyrimidines for the treatment of inflammatory Diseases | POUZET PASCALE (US) | 2012-05-03 | — | — | US | disclosed |
| US-20120108534-A1 | Dihydrothienopyrimidines for the treatment of inflammatory Diseases | POUZET PASCALE (US) | 2012-05-03 | — | — | US | disclosed |
| US-8114878-B2 | 6,7-dihydrothieno[3,2-d]pyrimidine for the treatment of inflammatory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-14 | — | — | US | disclosed |
| US-8114878-B2 | 6,7-dihydrothieno[3,2-d]pyrimidine for the treatment of inflammatory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-14 | — | — | US | disclosed |
| US-20120015920-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| EP-1182207-B1 | Non-covalent inhibitors of urokinase and blood vessel formation | DENDREON CORP (US) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006128184-A2 | PYRIMIDINE OR TRIAZINE FUSED BICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS-PHARMACEUTICALS, INC. (US) | 2006-11-30 | — | — | WO | disclosed |
| US-6586405-B2 | Therapy for blood disorders | CORVAS INTERNATIONAL, INC. | 2003-07-01 | — | — | US | disclosed |
| US-6541467-B1 | And at P1 have a six-membered heterocyclic ring having two ring nitrogen ring atoms and the remainder of the ring atoms carbon atoms. | CORVAS INTERNATIONAL, INC. | 2003-04-01 | — | — | US | disclosed |
| US-20020037857-A1 | Non-covalent inhibitors of urokinase and blood vessel formation | CORVAS INTERNATIONAL, INC. | 2002-03-28 | — | — | US | disclosed |
| EP-1182207-A2 | Non-covalent inhibitors of urokinase and blood vessel formation | CORVAS INTERNATIONAL, INC. (US) | 2002-02-27 | — | — | EP | disclosed |
| WO-2002014349-A2 | NON-COVALENT INHIBITORS OF UROKINASE AND BLOOD VESSEL FORMATION | CORVAS INTERNATIONAL, INC. (US) | 2002-02-21 | — | — | WO | disclosed |
| WO-2001079261-A1 | TETRAHYDRO-AZEPINONE DERIVATIVES AS THROMBIN INHIBITORS | CORVAS INTERNATIONAL, INC. (US) | 2001-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015920-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | MMP13, TIMP3, MMP3 | KDM4A 2119/4885CTSS 51/4885CTSK 66/4885 |
| US-20020037857-A1 | Non-covalent inhibitors of urokinase and blood vessel formation | PLAU, PLAT, PLG | KDM4A 2135/4885CTSS 242/4885CTSK 54/4885 |
| US-20120108534-A1 | Dihydrothienopyrimidines for the treatment of inflammatory Diseases | DPYD, DHFR, TPMT | KDM4A 3954/4885CTSS 2872/4885CTSK 4281/4885 |
| US-20140005154-A1 | 6,7-Dihydrothieno[3,2-d]pyrimidine for the Treatment of Inflammatory Diseases | DPYD, TYMS, TPMT | KDM4A 4249/4885CTSS 2630/4885CTSK 3858/4885 |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | KDM4A 2119/4885CTSS 51/4885CTSK 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.